Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Everybody, I'm Matthew Harrison, one of the Biotech analyst here at Morgan Stanley. Very pleased to have you join day 1 of our virtual conference and pleased to get started off with Genmab. And Jan van de Winkel, the CEO and President from Genmab. Just quickly before we start, I just need to read a disclosure statement.
Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. And with that, Jan, I'm going to turn it over to you to make a couple of minutes of opening remarks, and then we can jump into the Q&A.
/-- -
Thanks, Matthew. Good morning, everybody. We are delighted to be at this meeting. So Genmab had a very strong first half of the year and is on track, I think, for an excellent second half. We had,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |